LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Home・Aandelen Lijst・Celsion Corp

Celsion Corp

Gesloten

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken
By Trading Economics
Werknemers	25

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-9.9M 938K
Vorige openingsprijs	0
Vorige sluitingsprijs	0

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 nov 2025, 21:34 UTC

Winsten

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov 2025, 23:45 UTC

Marktinformatie

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov 2025, 23:42 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov 2025, 23:41 UTC

Marktinformatie

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov 2025, 23:24 UTC

Winsten

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov 2025, 23:24 UTC

Winsten

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov 2025, 23:23 UTC

Winsten

JBS NV 3Q EPS 52c >JBS

13 nov 2025, 23:23 UTC

Winsten

JBS NV 3Q Sales $22.6B >JBS

13 nov 2025, 23:04 UTC

Marktinformatie

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov 2025, 22:02 UTC

Winsten

Nu Holdings 3Q Net $783M >NU

13 nov 2025, 22:01 UTC

Winsten

Nu Holdings 3Q Rev $4.2B >NU

13 nov 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov 2025, 21:50 UTC

Winsten

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov 2025, 21:33 UTC

Marktinformatie

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov 2025, 21:33 UTC

Winsten

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov 2025, 21:31 UTC

Winsten

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov 2025, 21:25 UTC

Winsten

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov 2025, 21:25 UTC

Winsten

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov 2025, 21:23 UTC

Winsten

Intchains Group 3Q Rev $1.3M >ICG

13 nov 2025, 21:03 UTC

Winsten

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov 2025, 21:02 UTC

Winsten

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov 2025, 21:01 UTC

Winsten

Applied Materials 4Q Rev $6.8B >AMAT

13 nov 2025, 21:01 UTC

Winsten

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Celsion Corp - Dist in de afgelopen 3 maanden.

Financieel

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.